Risk factors for death from invasive pneumococcal disease, europe, 2010

Emerging Infectious Diseases

Volumn 21, Issue 3, 2015, Pages 417-425

  Navarro Torné, Adoración ^a,b   Dias, Joana Gomes ^a   Hruba, Frantiska ^a   Lopalco, Pier Luigi ^a   Pastore Celentano, Lucia ^a   Amato Gauci, Andrew J ^a   Sabbe, Martine ^c   Detcheva, Antoaneta ^c   Georgieva, Teodora ^c   Bagatzouni, Despo Pieridou ^c   Křížová, Pavla ^c   Valentiner Branth, Palle ^c   Fenoll, Asunción ^c   Virolainen Julkunen, Anni ^c   Georgakopoulou, Theano ^c   Tzanakaki, Georgina ^c   Melles, Márta ^c   Vickers, Imelda ^c   Cotter, Suzanne ^c   Humphreys, Hilary ^c   Kristinsson, Karl G ^c   Caporali, Maria Grazia ^c   D’Ancona, Fortunato Paolo ^c   Iannazzo, Stefania ^c   Pantosti, Annalisa ^c   Galajeva, Jelena ^c   Caruana, Paul ^c   Melillo, Jackie Maistre ^c   Fenech, Tanya Melillo ^c   De Melker, Hester ^c   Knol, Mirjam ^c   Van Der Ende, Arie ^c   Steinbakk, Martin ^c   Vestrheim, Didrik F ^c   Hryniewicz, Waleria ^c   Kuch, Alicja ^c   Paradowska Stankiewicz, Iwona ^c   Skoczynska, Anna ^c   Pana, Marina ^c   Henriques Normak, Birgitta ^c   Kraigher, Alenka ^c   Sočan, Maja ^c   Hupkova, Helena ^c   Macdonald, Eisin ^c   Slack, Mary P E ^c   Waight, Pauline A ^c   more..

^a EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c European Centre for Disease Prevention and Control ^*

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SURVEILLANCE; EUROPE; FATALITY; FEMALE; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MORTALITY; NEWBORN; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PUBLIC HEALTH SERVICE; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; CLASSIFICATION; DRUG EFFECTS; HEALTH SURVEY; HISTORY; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; RISK FACTOR; SEROTYPE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; EUROPE; FEMALE; HISTORY, 21ST CENTURY; HUMANS; INCIDENCE; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MORTALITY; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; RISK FACTORS; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84928651198     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2103.140634     Document Type: Article

References (40)

1. Lynch JP, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance and impact of vaccines. Curr Opin Pulm Med. 2010;16:217-25.
2. Scott JA, Hall AJ, Dagan R, Dixon JMS, Eykyn SJ, Fenoll A, et al. Serogroup-specifc epidemiology of Streptococcus pneumoniae: associations with age, sex and geography in 7000 episodes of invasive disease. Clin Infect Dis. 1996;22:973-81. http://dx.doi.org/10.1093/clinids/22.6.973
3. Weinberger DM, Grant LR, Steiner CA, Weatherholtz R, Santosham M, Viboud C, et al. Seasonal drivers of pneumococcal disease incidence: impact of bacterial carriage and viral activity. Clin Infect Dis. 2014;58:188-94. http://dx.doi.org/10.1093/cid/cit721
4. Launes C, Fernandez de Sevilla M, Selva L, Garcia Garcia JJ, Pallares R, Muñoz-Almagro C. Viral co-infection in children less than fve years old with invasive pneumococcal disease. Pediatr Infect Dis J. 2012;31:650-3. http://dx.doi.org/10.1097/INF.0b013e31824f25b0
5. Weinberger DM, Harboe ZB, Sanders EAM, Ndiritu M, Klugman KP, Rückinger S, et al. Risk of death from pneumococcal pneumonia is a stable serotype-associated property: a meta-analysis. Clin Infect Dis. 2010;51:692-9. http://dx.doi.org/10.1086/655828
6. Brueggemann AB, Griffths DT, Meats E, Peto T, Crook DW, Spratt BG. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specifc differences in invasive disease potential. J Infect Dis. 2003;187:1424-32. http://dx.doi.org/10.1086/374624
7. Pletz MW, Welte T, Klugman KP. The paradox in pneumococcal serotypes: highly invasive does not mean highly lethal. Eur Respir J. 2010;36:712-3. http://dx.doi.org/10.1183/09031936.00041210
8. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under fve: the pneumococcal global serotype project. PLoS Med. 2010;7:e1000348. http://dx.doi.org/10.1371/journal.pmed.1000348
9. Jansen AGSC, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, et al. Invasive pneumococcal disease among adults: association among serotypes, disease characteristics, and outcome. Clin Infect Dis. 2009;49:e23-9. http://dx.doi.org/10.1086/600045
10. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis. 2005;5:83-93. http://dx.doi.org/10.1016/S1473-3099(05)01280-6
11. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococ-cal conjugate vaccine. Vaccine. 2011;29:9127-31. http://dx.doi.org/10.1016/j.vaccine.2011.09.112
12. Palmu AA, Jokinen J, Nieminen H, Borys D, Nieminen H, Ruokokoski E, et al. Effectiveness of the ten-valent pneumococcal Haemophilus infuenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomized trial. Lancet. 2013;381:214-22. http://dx.doi.org/10.1016/S0140-6736(12)61854-6
13. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962-73. http://dx.doi.org/10.1016/S0140-6736(10)62225-8
14. Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis. 2012;12:207. http://dx.doi.org/10.1186/1471-2334-12-207
15. Reinert RR. The antimicrobial resistance profle of Streptococcus pneumoniae. Clin Microbiol Infect. 2009;15(Suppl 3):7-11. http://dx.doi.org/10.1111/j.1469-0691.2009.02724.x
16. Dagan R, Barkai G, Leibovitz E, Dreifuss E, Greenerg D. Will reduction of antibiotic use reduce antibiotic resistance? The pneumococcus paradigm. Pediatr Infect Dis J. 2006;25:981-6. http://dx.doi.org/10.1097/01.inf.0000239266.20642.26
17. European Antimicrobial Resistance Surveillance Network EARS-Net. Antimicrobial resistance interactive database (EARS-Net) [cited 2014 Mar 2]. http://www.ecdc.europa.eu/en/healthtopics/antimicrobialresistance/database/Pages/database.aspx
18. European Centre for Disease Prevention and Control. Surveillance of invasive pneumococcal disease in Europe, 2010 [cited 2014 Mar 3]. http://www.ecdc.europa.eu/en/publications/publications/invasive-pneumoccocal-disease-surveillance-2010.pdf
19. Luján M, Gallego M, Belmont Y, Fontanals D, Vallés J, Lisboa T, et al. Infuence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. Eur Respir J. 2010;36:1073-9. http://dx.doi.org/10.1183/09031936.00176309
20. Martens P, Worm SW, Lundgren B, Konradsen HB, Benfeld T. Serotype-specifc mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis. 2004;4:21. http://dx.doi.org/10.1186/1471-2334-4-21
21. Yu VL, Chiou CCC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003;37:230-7. http://dx.doi.org/10.1086/377534
22. Regev-Yochay G, Rahav G, Riesenberg K, Wiener-Well Y, Strahilevitz J, Stein M, et al. Initial effects of the national PCV7 childhood immunization program on adult invasive pneumococcal disease. PLoS ONE. 2014;9:e88406. http://dx.doi.org/10.1371/journal.pone.0088406
23. Simell B, Lahdenkari M, Reunanen A, Käyhty H, Väkeväinen M. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol. 2008;15:1391-7. http://dx.doi.org/10.1128/CVI.00110-08
24. European Centre for Disease Prevention and Control. Vaccine schedule. Recommended immunisations for pneumococcal disease [cited 2014 Apr 7]. http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
25. Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6:e1000081. http://dx.doi.org/10.1371/journal.pmed.1000081
26. Vallès X, Marcos A, Pinart M, Piñer R, Marco F, Mensa JM, et al. Hospitalized community-acquired pneumonia due to Streptococcus pneumoniae. Has resistance to antibiotics decreased? Chest. 2006;130:800-6. http://dx.doi.org/10.1378/chest.130.3.800
27. Roed C, Engsig FN, Omland LH, Skinhoj P, Obel N. Long-term mortality in patients diagnosed with pneumococcal meningitis: a Danish nationwide cohort. Am J Epidemiol. 2010;172:309-17. http://dx.doi.org/10.1093/aje/kwq126
28. Rückinger S, von Kries R, Siedler A, van der Linden M. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J. 2009;28:118-22. http://dx.doi.org/10.1097/INF.0b013e318187e215
29. Ladhani SN, Slack MPE, Andrews NJ, Waight PA, Borrow R, Miller E. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis. 2013;19:61-8. http://dx.doi.org/10.3201/eid1901.120741
30. Pichon B, Ladhani SN, Slack MPE, Segonds-Pichon A, Andrews NJ, Waight PA, et al. Changes in molecular epidemiology of Streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales. J Clin Microbiol. 2013;51:820-7. http://dx.doi.org/10.1128/JCM.01917-12
31. Li Y, Weinberger DM, Thompson CM, Trzciński K, Lipsitch M. Surface charge of Streptococcus pneumoniae predicts serotype distribution. Infect Immun. 2013;81:4519-24. http://dx.doi.org/10.1128/IAI.00724-13
32. van Hoek AJ, Andrews N, Waight PA, George R, Miller E. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS ONE. 2012;7:e39150. http://dx.doi.org/10.1371/journal.pone.0039150
33. Myint TTH, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30:127-51. http://dx.doi.org/10.1007/s12325-013-0007-6
34. Sjöström K, Spindler C, Örtqvist A, Kalin M, Sandgren A, Kühlmann-Berenzon S, et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis. 2006;42:451-9. http://dx.doi.org/10.1086/499242
35. Fenoll A, Aguilar L, Giménez MJ, Vicioso MD, Robledo O, Granizo JJ, et al. Susceptibility of recently collected Spanish pneumo-cocci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccine. Antimicrob Agents Chemother. 2010;54:2696-8. http://dx.doi.org/10.1128/AAC.01594-09
36. Gouveia EL, Reis JN, Flannery B, Cordeiro SM, Lima JBT, Pinheiro RM, et al. Clinical outcome of pneumococcal meningitis during the emergence of penicillin-resistant Streptococcus pneumoniae: an observational study. BMC Infect Dis. 2011;11:323. http://dx.doi.org/10.1186/1471-2334-11-323
37. Song JS, Choe PG, Song KH, Park WB, Park SW, Kim HB, et al. Risk factors for 30-day mortality in adult patients with pneumococ-cal bacteraemia, and the impact of antimicrobial resistance on clinical outcomes. Epidemiol Infect. 2012;140:1267-76. http://dx.doi.org/10.1017/S0950268811001816
38. Feldman C, Anderson RA. Bacteremic pneumococcal pneumonia: current therapeutic options. Drugs. 2011;71:131-53. http://dx.doi. org/10.2165/11585310-000000000-00000
39. Vila-Corcoles A, Ochoa-Gondar O. Preventing pneumococcal disease in the elderly. Recent advances in vaccines and implications for clinical practice. Drugs Aging. 2013;30:263-76. http://dx.doi.org/10.1007/s40266-013-0060-5
40. Miyaji EN, Sarno Oliveira ML, Carvalho E, Lee Ho P. Serotype-independent pneumococcal vaccines. Cell Mol Life Sci. 2013;70:3303-26. http://dx.doi.org/10.1007/s00018-012-1234-8